clinical trial · NCT04227600
A Study of JR-171 in Patients With Mucopolysaccharidosis I
JCR Pharmaceuticals Co., Ltd.·phase2·completed·n = 18
Mucopolysaccharidosis IJR-171 (lepunafusp alfa)
brief summary
Phase I/II, open-label, multicenter, multinational (Japan, Brazil and US),designed to evaluate the safety, pharmacokinetics and explore the efficacy for the treatment of mucopolysaccharidosis type I (MPS I).
started
Sep 1, 2020
primary completion
Aug 2, 2022
completion
Aug 2, 2022
last updated
Mar 19, 2025
detailed description
In the JR-171-102 study, subjects will receive either 2.0 or 4.0 mg/kg/week of JR-171 intravenously at the same dosages received at Week 12 of the JR-171-101 study.
official title
Phase I/II Study of JR-171 ㏌ Patients With Mucopolysaccharidosis Type I
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol